KiroVAX 004

Drug Profile

KiroVAX 004

Alternative Names: KiroVAX-004; TAPA pulsed dendritic cell vaccine - KiroVAX-004

Latest Information Update: 17 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Kiromic
  • Class Cancer vaccines; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Solid tumours

Most Recent Events

  • 18 Jul 2017 Phase-I/II clinical trials in Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (SC) (NCT02705703)
  • 07 Mar 2016 Preclinical trials in Solid tumours in USA (SC), before March 2016
  • 07 Mar 2016 Kiromic plans a phase I/II trial for Solid tumours (Metastatic disease, Second-line therapy or greater) in USA (NCT02705703)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top